Policy & Regulation
Evotec and Almirall agree multi-target alliance for medical dermatology
20 May 2022 -

Germany-based drug discovery and development company Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Spain-based Almirall S.A. (ALM), a global biopharmaceutical company focused on skin health, announced on Thursday a multi-target alliance in Medical Dermatology.

The companies aim to discover and develop novel therapeutics for severe skin diseases, including immune-mediated inflammatory conditions such as atopic dermatitis and non-melanoma skin cancer such as basal cell carcinoma.

The alliance is intended to leverage Evotec's fully integrated multimodality platform and combine it with Almirall's expertise in Medical Dermatology. Both partners will contribute drug targets in the research process. Leveraging the company's end-to-end integrated, AI/ML-driven EVOiR&D platform, Evotec will be responsible for drug discovery and pre-clinical development. Almirall will lead the clinical development and marketing.

Under the agreement, Evotec receives an undisclosed upfront payment, research payments, as well as success-based milestones of potentially up to EUR230m per programme and royalties on net sales in the high single-digit percentage range.

Dr Werner Lanthaler, Evotec chief executive officer, commented, 'We are very happy to enter this collaboration with Almirall, one of the leaders in the field of Medical Dermatology. The collaboration has the potential to deliver superior first-in-class therapeutic options for many patients suffering from severe skin diseases such as atopic dermatitis or basal cell carcinoma. We are looking forward to leveraging the complementary expertise of Evotec and Almirall in order to develop promising new drug candidates.'



Related Headlines